We have located links that may give you full text access.
Ex Vivo Lung Perfusion in Donation after Circulatory Death: A Post-Hoc Analysis of the NOVEL Trial.
Journal of Thoracic and Cardiovascular Surgery 2024 March 19
OBJECTIVE: Donation after circulatory death (DCD) donors offer the ability to expand the lung donor pool and ex vivo lung perfusion (EVLP) further contributes to this ability by allowing for additional evaluation and resuscitation of these extended criteria donors. We sought to determine the outcomes of recipients receiving organs from DCD EVLP donors in a multi-center setting.
METHODS: This was an unplanned post-hoc analysis of a multicenter, prospective, non-randomized trial that took place in 2011-2017 with 3-years of follow up. Patients were placed into three groups based off procurement strategy: brain-dead donor (BDD) (Control), BDD evaluated by EVLP and DCD donors evaluated by EVLP. The primary outcomes were severe primary graft dysfunction (PGD3) at 72 hours and survival. Secondary outcomes included select peri-operative outcomes, and 1-year and 3-years allograft function and quality of life measures.
RESULTS: The DCD EVLP group had significantly higher incidence of PGD3 at 72 hours (p=0.03), longer days on mechanical ventilation (p<0.001) and in-hospital length of stay (p=0.045). Survival at 3-years was: 76.5% (95% CI: 69.2%-84.7%) for the Control group, 68.3% (95% CI: 58.9%-79.1%) for the BDD group, and 60.7% (95% CI: 45.1%-81.8%) for the DCD group (p=0.36). At 3-year follow-up, presence observed bronchiolitis obliterans syndrome or quality of life metrics did not differ amongst the groups.
CONCLUSION: While DCD EVLP allografts might not be appropriate to transplant in every candidate recipient, the expansion of their use might afford recipients stagnant on the waitlist a viable therapy.
METHODS: This was an unplanned post-hoc analysis of a multicenter, prospective, non-randomized trial that took place in 2011-2017 with 3-years of follow up. Patients were placed into three groups based off procurement strategy: brain-dead donor (BDD) (Control), BDD evaluated by EVLP and DCD donors evaluated by EVLP. The primary outcomes were severe primary graft dysfunction (PGD3) at 72 hours and survival. Secondary outcomes included select peri-operative outcomes, and 1-year and 3-years allograft function and quality of life measures.
RESULTS: The DCD EVLP group had significantly higher incidence of PGD3 at 72 hours (p=0.03), longer days on mechanical ventilation (p<0.001) and in-hospital length of stay (p=0.045). Survival at 3-years was: 76.5% (95% CI: 69.2%-84.7%) for the Control group, 68.3% (95% CI: 58.9%-79.1%) for the BDD group, and 60.7% (95% CI: 45.1%-81.8%) for the DCD group (p=0.36). At 3-year follow-up, presence observed bronchiolitis obliterans syndrome or quality of life metrics did not differ amongst the groups.
CONCLUSION: While DCD EVLP allografts might not be appropriate to transplant in every candidate recipient, the expansion of their use might afford recipients stagnant on the waitlist a viable therapy.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app